europe epinephrine Market

Europe, the epinephrine market, is anticipated to reach US$ 1,238.80 Mn in 2027 from US$ 680.01 Mn in 2019. The market is projected to grow with a CAGR of 8.0% from 2020-2027.

The epinephrine market is growing primarily due to the fast growth of epinephrine technology market in Europe and the growing prevalence of anaphylaxis cases in the European region that are boosting the market over the years. Restraining factors, such lack of availability of epinephrine drug, are likely to damage the growth of the market in the coming years. On the other hand, growing R&D expenditure for growing pipeline of epinephrine is expected to have a positive impact on the growth of the epinephrine market in the Europe coming years.

Anaphylaxis is a severe, life?threatening allergic reaction characterized by symptoms such as skin redness and itching, swallowing and breathing difficulties, wheezing, rapid breathing rate (tachypnoea), accelerated heart rate (tachycardia), and falling blood pressure. It may involve multiple systems of human body. Anaphylaxis is caused by exposure to an allergen (foods, insect stings, or medicines) that is recognized as a non-self by a human body.

The incidence of anaphylaxis is increasing, More than 1 billion people in the world suffered from respiratory diseases in 2018, asthma to which is a major contributor, according to the World Health Organization (WHO). According to NCBI, Anaphylaxis is a common problem, affecting an estimated 1 in 300 of the European population at some time in their lives. Future research needs to focus on a better understanding of the trends across Europe and identifying those most likely to experience fatal reactions. Anaphylaxis requires immediate medical treatment, and it can turn lethal if not treated properly. Allergies put an economic burden on healthcare systems in many countries; Anaphylaxis requires immediate medical treatment, and it can turn lethal if not treated properly. Therefore, the demand for epinephrine is expected to increase during the forecast period.

In 2019, the auto-injectors accounted for the largest market share in the European epinephrine market. Epinephrine auto-injectors are measured dosages and are also used to treat life-threatening allergic reactions. The epinephrine auto-injectors can be self-administered. The auto-injectors segment is also estimated to mark the highest CAGR in the market during the forecast period, owing to the increasing technological development that is enabling the alternative treatment of anaphylaxis by the various generic drugs.

In 2019, the anaphylaxis segment, held the most significant market share of the epinephrine market by the application. This segment is also anticipated to hold a considerable portion of the market in 2027, owing to the need for treatment of anaphylaxis and other allergies for the people. The segment is also anticipated to witness growth at a significant rate during the forecast period.

Some of the significant primary and secondary sources for epinephrine included in the report are World Health Organization (WHO), Food and Drug Administration (FDA), Food Allergy Research & Education, Centers for Disease Control and Prevention (CDC), National Center for Biotechnology Information (NCBI)